1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Sun Sees New Prescriptions Drought Amid COVID-19

But Situation Improving And Ilumya Solid

 
• By Anju Ghangurde

Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.

Prescription
Sun expects a challenging Q1 across pharma in India • Source: Shutterstock

Sun Pharmaceutical Industries’ earnings call for the fourth quarter of fiscal 2020 provided a glimpse of the challenging environment that the Indian firm, like the rest of the industry, was operating in amid COVID-19, both on home turf and in the US.

While a significant proportion of physicians stayed away from their clinics in India and sales personnel were initially grounded amid the local lock-down and product ramp-ups and doctor calls were impacted in Q4 in the US as well,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.